Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NTRK1
REST API REST API
Homo sapiens
NTRK1 is differentially expressed in 148 experiments: 62 organism parts: kidney, blood, ... (60 more);, 105 disease states: normal, chronic myelogenous leukemia, ... (103 more);, 43 cell types 126 cell lines 20 compound treatments and 66 other conditions.
Synonyms MTC, TRKA, TRK
Orthologs F1MC14_BOVIN (Bos taurus)   Ntrk1 (Rattus norvegicus)   Ntrk1 (Mus musculus)   ntrk1 (Danio rerio)   NTRK1 (Gallus gallus)   sev (Drosophila melanogaster)   ntrk1 (Xenopus laevis)   NTRK1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, membrane, Golgi membrane, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, cell differentiation, activation of MAPKK activity, ATP binding, Ras protein signal transduction, small GTPase mediated signal transduction, multicellular organismal development, integral to plasma membrane, activation of phospholipase C activity, receptor activity, nucleotide binding, endosome, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, nervous system development, cell surface, protein kinase activity, activation of adenylate cyclase activity, negative regulation of neuron apoptosis, neurotrophin binding, B cell differentiation, cellular response to growth factor stimulus, mechanoreceptor differentiation, neurotrophin receptor activity, nerve growth factor receptor signaling pathway, protein autophosphorylation, protein phosphorylation, phosphatidylinositol-mediated signaling
InterPro Term Cys-rich_flank_reg_C, Prot_kinase_cat_dom, Ig-like, Tyr_kinase_neurotrophic_rcpt_1, Tyr_kinase_NGF_rcpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY, INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA, THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC
UniProt Accession P04629, A6NF12, E9PQG0
Search EB-eye ENSG00000198400
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MTAB-37, E-GEOD-96, E-GEOD-5823, ... (10 experiments)

Factor Value U/D Experiments
HL-60
2
E-GEOD-24147, E-GEOD-5258
NCIH2405
1
E-MTAB-37
ARH77
1
E-MTAB-37
NCIH1651
1
E-MTAB-37
SW1116
1
E-MTAB-37
cultured polyclonal CD31- ADASCs
1
E-MTAB-62
120 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, ... (26 experiments)

Factor Value U/D Experiments
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
CD41 negative portion
1
E-MEXP-1546
spermatid
1
E-TABM-130
n/a
1
E-MTAB-24
B lymphocyte
1
E-GEOD-6691
mononuclear cell
1
E-GEOD-7307
37 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1869, E-MEXP-66, E-MTAB-680, ... (26 experiments)

Factor Value U/D Experiments
normal
1
4
E-TABM-282, E-GEOD-13987, E-GEOD-5390, E-MEXP-561, E-GEOD-2514 ... (5 experiments)
chronic myelogenous leukemia
3
E-MTAB-37, E-GEOD-96, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
neuroblastoma
3
E-MTAB-37, E-GEOD-1825, E-MTAB-62
Becker muscular dystrophy
1
E-GEOD-3307
carcinoma in situ
1
E-MTAB-62
99 more value(s).


Compound treatment

studied in E-GEOD-3720, E-GEOD-15811, E-GEOD-5099, E-MEXP-941, E-GEOD-5339, ... (13 experiments)

Factor Value U/D Experiments
bacterial endotoxin
1
1
E-GEOD-3284
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
immunoglobulin E
1
E-GEOD-3982
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
glutamine
1
E-MEXP-941
14 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd38
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-GEOD-1563, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-666, E-MEXP-1648, ... (20 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-7114

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-17204

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Stimulation
studied in E-GEOD-4883

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.473 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM